Use of Systemic Therapies for Treatment of Psoriasis in Patients with a History of Treated Solid Tumours: Inference-Based Guidance from a Multidisciplinary Expert Panel.
Cancer
Evidence-based dermatology
Malignancy
Medical education
Psoriasis
Solid tumours
Journal
Dermatology and therapy
ISSN: 2193-8210
Titre abrégé: Dermatol Ther (Heidelb)
Pays: Switzerland
ID NLM: 101590450
Informations de publication
Date de publication:
Apr 2023
Apr 2023
Historique:
received:
24
01
2023
accepted:
15
02
2023
medline:
18
3
2023
pubmed:
18
3
2023
entrez:
17
3
2023
Statut:
ppublish
Résumé
Patients with treated solid tumours (TSTs) are a highly heterogeneous population at an increased risk for malignancy compared with the general population. When treating psoriasis in patients with a history of TSTs, clinicians are concerned about the immunosuppressive nature of psoriasis therapies, the possibility of augmenting cancer recurrence/progression, and infectious complications. No direct, high-level evidence exists to address these concerns. We aim to provide a structured framework supporting healthcare professional and patient discussions on the risks and benefits of systemic psoriasis therapy in patients with previously TSTs. Our goal was to address the clinically important question, "In patients with TSTs, does therapy with systemic agents used for psoriasis increase the risk of malignancy or malignancy recurrence?" We implemented an inference-based approach relying on indirect evidence when direct clinical trial and real-world data were absent. We reviewed indirect evidence supporting inferences on the status of immune function in patients with TSTs. Recommendations on systemic psoriasis therapies in patients with TSTs were derived using an inferential heuristic. We identified five indirect indicators of iatrogenic immunosuppression informed by largely independent bodies of evidence: (1) overall survival, (2) rate of malignancies with psoriasis and systemic psoriasis therapies, (3) rate of infections with psoriasis and systemic psoriasis therapies, (4) common disease biochemical pathways for solid tumours and systemic psoriasis therapies, and (5) solid organ transplant outcomes. On the basis of review of the totality of this data, we provided inference-based conclusions and ascribed level of support for each statement. Prior to considering new therapies for psoriasis, an understanding of cancer prognosis should be addressed. Patients with TSTs and a good cancer prognosis will have similar outcomes to non-TST patients when treated with systemic psoriasis therapies. For patients with TSTs and a poor cancer prognosis, the quality-of-life benefits of treating psoriasis may outweigh the theoretical risks. Patients with previously treated cancer have a higher chance of cancer recurrence compared with the general population. With cancer incidence rising worldwide, doctors across medical specialities will need to treat other medical conditions, including inflammatory diseases such as psoriasis, in these patients. Effective systemic therapies for psoriasis reduce immune cell activity. Accordingly, there are concerns that treatments for psoriasis could worsen cancer recurrence/progression and infectious complications. There is not enough quality evidence to make broad recommendations for treating other inflammatory conditions in patients with a history of cancer. To guide patient and doctor discussions, we asked: what are effective and safe treatments when patients with treated solid tumours need systemic therapy (pills or injections) for their psoriasis? We focused on patients with solid tumours and excluded blood and skin cancers. Our panel of experts, including 12 dermatologists and 3 medical oncologists, reviewed direct and indirect evidence to answer this question. Considering the totality of evidence reviewed, the expert panel drafted and rated their level of support for opinion statements on important considerations in treating patients with psoriasis who have a history of solid tumours. By making inferences on systemic psoriasis therapies in this heterogeneous population, we take the onus off individual physicians to review the indirect data. This process may help answer questions in other disease populations where direct evidence is scarce or absent. To support treatment decisions, doctors should have a guided conversation with the patient and their family on a case-by-case basis about the risks and benefits of treatment.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with treated solid tumours (TSTs) are a highly heterogeneous population at an increased risk for malignancy compared with the general population. When treating psoriasis in patients with a history of TSTs, clinicians are concerned about the immunosuppressive nature of psoriasis therapies, the possibility of augmenting cancer recurrence/progression, and infectious complications. No direct, high-level evidence exists to address these concerns.
OBJECTIVES
OBJECTIVE
We aim to provide a structured framework supporting healthcare professional and patient discussions on the risks and benefits of systemic psoriasis therapy in patients with previously TSTs. Our goal was to address the clinically important question, "In patients with TSTs, does therapy with systemic agents used for psoriasis increase the risk of malignancy or malignancy recurrence?"
METHODS
METHODS
We implemented an inference-based approach relying on indirect evidence when direct clinical trial and real-world data were absent. We reviewed indirect evidence supporting inferences on the status of immune function in patients with TSTs. Recommendations on systemic psoriasis therapies in patients with TSTs were derived using an inferential heuristic.
RESULTS
RESULTS
We identified five indirect indicators of iatrogenic immunosuppression informed by largely independent bodies of evidence: (1) overall survival, (2) rate of malignancies with psoriasis and systemic psoriasis therapies, (3) rate of infections with psoriasis and systemic psoriasis therapies, (4) common disease biochemical pathways for solid tumours and systemic psoriasis therapies, and (5) solid organ transplant outcomes. On the basis of review of the totality of this data, we provided inference-based conclusions and ascribed level of support for each statement.
CONCLUSIONS
CONCLUSIONS
Prior to considering new therapies for psoriasis, an understanding of cancer prognosis should be addressed. Patients with TSTs and a good cancer prognosis will have similar outcomes to non-TST patients when treated with systemic psoriasis therapies. For patients with TSTs and a poor cancer prognosis, the quality-of-life benefits of treating psoriasis may outweigh the theoretical risks.
Patients with previously treated cancer have a higher chance of cancer recurrence compared with the general population. With cancer incidence rising worldwide, doctors across medical specialities will need to treat other medical conditions, including inflammatory diseases such as psoriasis, in these patients. Effective systemic therapies for psoriasis reduce immune cell activity. Accordingly, there are concerns that treatments for psoriasis could worsen cancer recurrence/progression and infectious complications. There is not enough quality evidence to make broad recommendations for treating other inflammatory conditions in patients with a history of cancer. To guide patient and doctor discussions, we asked: what are effective and safe treatments when patients with treated solid tumours need systemic therapy (pills or injections) for their psoriasis? We focused on patients with solid tumours and excluded blood and skin cancers. Our panel of experts, including 12 dermatologists and 3 medical oncologists, reviewed direct and indirect evidence to answer this question. Considering the totality of evidence reviewed, the expert panel drafted and rated their level of support for opinion statements on important considerations in treating patients with psoriasis who have a history of solid tumours. By making inferences on systemic psoriasis therapies in this heterogeneous population, we take the onus off individual physicians to review the indirect data. This process may help answer questions in other disease populations where direct evidence is scarce or absent. To support treatment decisions, doctors should have a guided conversation with the patient and their family on a case-by-case basis about the risks and benefits of treatment.
Autres résumés
Type: plain-language-summary
(eng)
Patients with previously treated cancer have a higher chance of cancer recurrence compared with the general population. With cancer incidence rising worldwide, doctors across medical specialities will need to treat other medical conditions, including inflammatory diseases such as psoriasis, in these patients. Effective systemic therapies for psoriasis reduce immune cell activity. Accordingly, there are concerns that treatments for psoriasis could worsen cancer recurrence/progression and infectious complications. There is not enough quality evidence to make broad recommendations for treating other inflammatory conditions in patients with a history of cancer. To guide patient and doctor discussions, we asked: what are effective and safe treatments when patients with treated solid tumours need systemic therapy (pills or injections) for their psoriasis? We focused on patients with solid tumours and excluded blood and skin cancers. Our panel of experts, including 12 dermatologists and 3 medical oncologists, reviewed direct and indirect evidence to answer this question. Considering the totality of evidence reviewed, the expert panel drafted and rated their level of support for opinion statements on important considerations in treating patients with psoriasis who have a history of solid tumours. By making inferences on systemic psoriasis therapies in this heterogeneous population, we take the onus off individual physicians to review the indirect data. This process may help answer questions in other disease populations where direct evidence is scarce or absent. To support treatment decisions, doctors should have a guided conversation with the patient and their family on a case-by-case basis about the risks and benefits of treatment.
Identifiants
pubmed: 36929121
doi: 10.1007/s13555-023-00905-3
pii: 10.1007/s13555-023-00905-3
pmc: PMC10060504
doi:
Types de publication
Journal Article
Langues
eng
Pagination
867-889Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4:1553–68.
doi: 10.1001/jamaoncol.2018.2706
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71:7–33.
pubmed: 33433946
doi: 10.3322/caac.21654
National Comprehensive Cancer Network. Survivorship (Version 1.2022) https://www.nccn.org/professionals/physician_gls/pdf/survivorship.pdf . Accessed 9 Sep 2022
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49.
pubmed: 33538338
doi: 10.3322/caac.21660
Syriopoulou E, Bower H, Andersson TM-L, Lambert PC, Rutherford MJ. Estimating the impact of a cancer diagnosis on life expectancy by socio-economic group for a range of cancer types in England. Br J Cancer. 2017;117:1419–26.
pubmed: 28898233
pmcid: 5672926
doi: 10.1038/bjc.2017.300
Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New malignancies among cancer survivors: SEER Cancer Registries, 1973–2000. National Cancer Institute, NIH Publ. No. 05-5302. Bethesda, MD, 2006.
Mastorino L, Dapavo P, Avallone G, Merli M, Cariti C, Rubatto M, et al. Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden? J Dermatol Treat. 2021;1–8.
Valenti M, Pavia G, Gargiulo L, Facheris P, Sanna F, Borroni RG, et al. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: long-term safety in a single- center real-life population. J Dermatol Treat. 2021;1–5.
Bellinato F, Gisondi P, Maurelli M, Girolomoni G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: a case series with systematic literature review. Dermatol Ther. 2021;34: e14889.
pubmed: 33595861
doi: 10.1111/dth.14889
Papp K, Gooderham M, Lynde C, Poulin Y, Beecker J, Dutz J, et al. Practical and relevant guidelines for the management of psoriasis: an inference-based methodology. Dermatol Ther (Heidelb). 2022;12:253–65.
pubmed: 34939178
doi: 10.1007/s13555-021-00642-5
Vick SG. Degrees of belief: subjective probability and engineering judgment. Reston: American Society of Civil Engineers; 2002.
R Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2014.
Schneider G, Schmidt-Supprian M, Rad R, Saur D. Tissue-specific tumorigenesis: context matters. Nat Rev Cancer. 2017;17:239–53.
pubmed: 28256574
pmcid: 5823237
doi: 10.1038/nrc.2017.5
Jeffes EW, Weinstein GD. Methotrexate and other chemotherapeutic agents used to treat psoriasis. Dermatol Clin. 1995;13:875–90.
pubmed: 8785891
doi: 10.1016/S0733-8635(18)30050-0
Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19:345–61.
pubmed: 29256113
doi: 10.1007/s40257-017-0336-3
Blackadar CB. Historical review of the causes of cancer. WJCO. 2016;7:54.
pubmed: 26862491
pmcid: 4734938
doi: 10.5306/wjco.v7.i1.54
Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci USA. 1995;92:5258–65.
pubmed: 7777494
pmcid: 41674
doi: 10.1073/pnas.92.12.5258
DePinho RA. The age of cancer. Nature. 2000;408:248–54.
pubmed: 11089982
doi: 10.1038/35041694
White MC, Holman DM, Boehm JE, Peipins LA, Grossman M, Jane HS. Age and cancer risk. Am J Prev Med. 2014;46:S7-15.
pubmed: 24512933
pmcid: 4544764
doi: 10.1016/j.amepre.2013.10.029
Danaei G, Vander Hoorn S, Lopez AD, Murray CJ, Ezzati M. Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. The Lancet. 2005;366:1784–93.
doi: 10.1016/S0140-6736(05)67725-2
Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. 1981;66:117
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 2018;32:1267–84.
pubmed: 30275043
pmcid: 6169832
doi: 10.1101/gad.314617.118
Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51:27–41.
pubmed: 31315034
pmcid: 6831096
doi: 10.1016/j.immuni.2019.06.025
De Marzo AM, Platz EA, Sutcliffe S, Xu J, Grönberg H, Drake CG, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer. 2007;7:256–69.
pubmed: 17384581
pmcid: 3552388
doi: 10.1038/nrc2090
Sfanos KS, De Marzo AM. Prostate cancer and inflammation: the evidence: prostate cancer and inflammation. Histopathology. 2012;60:199–215.
pubmed: 22212087
pmcid: 4029103
doi: 10.1111/j.1365-2559.2011.04033.x
de Bono JS, Guo C, Gurel B, De Marzo AM, Sfanos KS, Mani RS, et al. Prostate carcinogenesis: inflammatory storms. Nat Rev Cancer. 2020;20:455–69.
pubmed: 32546840
doi: 10.1038/s41568-020-0267-9
Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slingerland JM. Obesity and adverse breast cancer risk and outcome: Mechanistic insights and strategies for intervention: breast cancer, inflammation, and obesity. CA Cancer J Clin. 2017;67:378–97.
pubmed: 28763097
pmcid: 5591063
doi: 10.3322/caac.21405
Howe LR. Inflammation and breast cancer. Cyclooxygenase/prostaglandin signaling and breast cancer. Breast Cancer Res. 2007;9:210.
pubmed: 17640394
pmcid: 2206709
doi: 10.1186/bcr1678
De Nardo DG, Coussens LM. Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007;9:212.
doi: 10.1186/bcr1746
Cole SW. Chronic inflammation and breast cancer recurrence. JCO. 2009;27:3418–9.
doi: 10.1200/JCO.2009.21.9782
Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8:605–15.
pubmed: 18402527
doi: 10.1586/14737140.8.4.605
Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, et al. Smoking and lung cancer: the role of inflammation. Proc Am Thorac Soc. 2008;5:811–5.
pubmed: 19017734
pmcid: 4080902
doi: 10.1513/pats.200809-100TH
Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. Myer L, editor. PLoS ONE. 2011;6: e17479.
pubmed: 21483846
pmcid: 3069026
doi: 10.1371/journal.pone.0017479
Conway EM, Pikor LA, Kung SHY, Hamilton MJ, Lam S, Lam WL, et al. Macrophages, inflammation, and lung cancer. Am J Respir Crit Care Med. 2016;193:116–30.
pubmed: 26583808
doi: 10.1164/rccm.201508-1545CI
Engels EA, Wu X, Gu J, Dong Q, Liu J, Spitz MR. Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res. 2007;67:6520–7.
pubmed: 17596594
doi: 10.1158/0008-5472.CAN-07-0370
Grivennikov SI. Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol. 2013;35:229–44.
pubmed: 23161445
doi: 10.1007/s00281-012-0352-6
Wang S, Liu Z, Wang L, Zhang X. NF-kappaB signaling pathway, inflammation and colorectal cancer. Mol Immunol. 2009;6:8.
Rhodes JM, Campbell BJ. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002;8:10–6.
pubmed: 11796261
doi: 10.1016/S1471-4914(01)02194-3
Kraus S, Arber N. Inflammation and colorectal cancer. Curr Opin Pharmacol. 2009;9:405–10.
pubmed: 19589728
doi: 10.1016/j.coph.2009.06.006
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23:1097–104.
pubmed: 16611269
doi: 10.1111/j.1365-2036.2006.02854.x
Dai J, Jiang M, Wang X-P, Tian L. Inflammation-related pancreatic carcinogenesis: mechanisms and clinical potentials in advances. Pancreas. 2017;46:973–85.
pubmed: 28796135
doi: 10.1097/MPA.0000000000000886
Liu Y, Cao X. Immunosuppressive cells in tumor immune escape and metastasis. J Mol Med. 2016;94:509–22.
pubmed: 26689709
doi: 10.1007/s00109-015-1376-x
Zheng L, Qin S, Si W, Wang A, Xing B, Gao R, et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science. 2021;374:abe6474.
pubmed: 34914499
doi: 10.1126/science.abe6474
Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest. 2015;125:3347–55.
pubmed: 26325032
pmcid: 4588298
doi: 10.1172/JCI80007
Sacdalan DB, Lucero JA. The association between inflammation and immunosuppression: implications for ICI biomarker development. Onco Targets Ther. 2021;14:2053–64.
pubmed: 33776452
pmcid: 7987319
doi: 10.2147/OTT.S278089
Waldman A, Schmults C. Cutaneous squamous cell carcinoma. Hematol Oncol Clin N Am. 2019;33:1–12.
doi: 10.1016/j.hoc.2018.08.001
Ridker PM, MacFadyen JG, Thuren T, Everett BM, Libby P, Glynn RJ, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1833–42.
pubmed: 28855077
doi: 10.1016/S0140-6736(17)32247-X
Gogna S, Ramakrishna K, John S. Post transplantation cancer. StatPearls. Treasure Island: StatPearls Publishing; 2021.
Hall EC, Pfeiffer RM, Segev DL, Engels EA. Cumulative incidence of cancer after solid organ transplantation: cancer incidence after transplantation. Cancer. 2013;119:2300–8.
pubmed: 23559438
doi: 10.1002/cncr.28043
Sprangers B, Nair V, Launay-Vacher V, Riella LV, Jhaveri KD. Risk factors associated with post–kidney transplant malignancies: an article from the Cancer-Kidney International Network. Clin Kidney J. 2018;11:315–29.
pubmed: 29942495
doi: 10.1093/ckj/sfx122
Rossi AP, Klein CL. Posttransplant malignancy. Surg Clin N Am. 2019;99:49–64.
pubmed: 30471741
doi: 10.1016/j.suc.2018.09.004
Manickavasagar R, Thuraisingham R. Post renal-transplant malignancy surveillance. Clin Med. 2020;20:142–5.
doi: 10.7861/clinmed.2019-0423
Shtraichman O, Ahya VN. Malignancy after lung transplantation. Ann Transl Med. 2020;8:416–416.
pubmed: 32355860
pmcid: 7186714
doi: 10.21037/atm.2020.02.126
Farrugia D, Mahboob S, Cheshire J, Begaj I, Khosla S, Ray D, et al. Malignancy-related mortality following kidney transplantation is common. Kidney Int. 2014;85:1395–403.
pubmed: 24257690
doi: 10.1038/ki.2013.458
Stallone G, Infante B, Grandaliano G. Management and prevention of post-transplant malignancies in kidney transplant recipients: Table 1. Clin Kidney J. 2015;8:637–44.
pubmed: 26413294
pmcid: 4581374
doi: 10.1093/ckj/sfv054
Gibson JAG, Cordaro A, Dobbs TD, Griffiths R, Akbari A, Whitaker S, et al. The association between immunosuppression and skin cancer in solid organ transplant recipients: a control-matched cohort study of 2,852 patients. Eur J Dermatol. 2021;31:712–21.
pubmed: 34427560
doi: 10.1684/ejd.2021.4108
Wong G, Chapman JR, Craig JC. Death from cancer: a sobering truth for patients with kidney transplants. Kidney Int. 2014;85:1262–4.
pubmed: 24875547
doi: 10.1038/ki.2013.494
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, et al. Predicted cure and survival among transplant recipients with a previous cancer diagnosis. J Clin Oncol. 2021;39:4039–48.
pubmed: 34678077
pmcid: 8677988
doi: 10.1200/JCO.21.01195
Engels EA, Haber G, Hart A, Lynch CF, Li J, Pawlish KS, et al. Solid organ transplantation and survival among individuals with a history of cancer. Cancer Epidemiol Biomark Prev. 2021;30:1312–9.
doi: 10.1158/1055-9965.EPI-21-0044
Acuna SA, Lam W, Daly C, Kim SJ, Baxter NN. Cancer evaluation in the assessment of solid organ transplant candidates: a systematic review of clinical practice guidelines. Transplant Rev (Orlando). 2018;32:29–35.
pubmed: 29169958
doi: 10.1016/j.trre.2017.10.002
Livingston-Rosanoff D, Foley DP, Leverson G, Wilke LG. Impact of pre-transplant malignancy on outcomes after kidney transplantation: united network for organ sharing database analysis. J Am Coll Surg. 2019;229:568–79.
pubmed: 31666186
pmcid: 6879822
doi: 10.1016/j.jamcollsurg.2019.06.001
Liauw SL, Ham SA, Das LC, Rudra S, Packiam VT, Koshy M, et al. Prostate cancer outcomes following solid-organ transplantation: a SEER-Medicare analysis. J Natl Cancer Inst. 2020;112:847–54.
pubmed: 31728517
doi: 10.1093/jnci/djz221
Al-Adra DP, Hammel L, Roberts J, Woodle ES, Levine D, Mandelbrot D, et al. Pretransplant solid organ malignancy and organ transplant candidacy: a consensus expert opinion statement. Am J Transplant. 2021;21:460–74.
pubmed: 32969590
doi: 10.1111/ajt.16318
Tsai W-L, Chung RT. Viral hepatocarcinogenesis. Oncogene. 2010;29:2309–24.
pubmed: 20228847
pmcid: 3148694
doi: 10.1038/onc.2010.36
Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology. 2012;142:1274–8.
pubmed: 22537433
doi: 10.1053/j.gastro.2012.01.045
Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64:S84-101.
pubmed: 27084040
doi: 10.1016/j.jhep.2016.02.021
Fung J, Lai C-L, Yuen M-F. Hepatitis B and C virus-related carcinogenesis. Clin Microbiol Infect. 2009;15:964–70.
pubmed: 19874379
doi: 10.1111/j.1469-0691.2009.03035.x
Williams VM, Filippova M, Soto U, Duerksen-Hughes PJ. HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress. Futur Virol. 2011;6:45–57.
doi: 10.2217/fvl.10.73
Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human papillomavirus infection and cervical cancer: epidemiology, screening, and vaccination—review of current perspectives. J Oncol. 2019;2019:1–11.
doi: 10.1155/2019/3257939
Wang X, Huang X, Zhang Y. Involvement of human papillomaviruses in cervical cancer. Front Microbiol. 2018;9:2896.
pubmed: 30546351
pmcid: 6279876
doi: 10.3389/fmicb.2018.02896
Martinez OM, de Gruijl FR. Molecular and immunologic mechanisms of cancer pathogenesis in solid organ transplant recipients. Am J Transplant. 2008;8:2205–11.
pubmed: 18801025
doi: 10.1111/j.1600-6143.2008.02368.x
Raaschou P, Söderling J, Turesson C, Askling J. Tumor necrosis factor inhibitors and cancer recurrence in Swedish patients with rheumatoid arthritis. Ann Intern Med. 2018;169:291–9.
pubmed: 30105374
doi: 10.7326/M17-2812
Bessaleli E, Scheinfeld N, Kroumpouzos G. Squamous cell carcinoma of the cervix arising in a patient on adalimumab—a need for cervical screenings in patients on tumor necrosis factor inhibitors. Dermatology Online Journal [Internet]. 2018;24. https://escholarship.org/uc/item/3fs049h2 . Accessed 2022 Jul 15.
Chiesa Fuxench ZC, Shin DB, Ogdie Beatty A, Gelfand JM. The risk of cancer in patients with psoriasis: a population-based cohort study in the health improvement network. JAMA Dermatol. 2016;152:282.
pubmed: 26676102
pmcid: 5273859
doi: 10.1001/jamadermatol.2015.4847
Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156:421.
pubmed: 32074260
pmcid: 7042857
doi: 10.1001/jamadermatol.2020.0024
Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Incidence rates of malignancies and hospitalized infectious events in patients with psoriasis with or without treatment and a general population in the U.S.A.: 2005–09. Br J Dermatol. 2014;170:366–73.
pubmed: 24251402
doi: 10.1111/bjd.12744
Kimball AB, Schenfeld J, Accortt NA, Anthony MS, Rothman KJ, Pariser D. Cohort study of malignancies and hospitalized infectious events in treated and untreated patients with psoriasis and a general population in the United States. Br J Dermatol. 2015;173:1183–90.
pubmed: 26265015
doi: 10.1111/bjd.14068
Geller S, Xu H, Lebwohl M, Nardone B, Lacouture ME, Kheterpal M. Malignancy risk and recurrence with psoriasis and its treatments: a concise update. Am J Clin Dermatol. 2018;19:363–75.
pubmed: 29260411
pmcid: 5948118
doi: 10.1007/s40257-017-0337-2
Loft ND, Vaengebjerg S, Skov L. Cancer risk in patients with psoriasis: should we be paying more attention? Expert Rev Clin Immunol. 2020;16:479–92.
pubmed: 32279582
doi: 10.1080/1744666X.2020.1754194
Gandhi SA, Kampp J. Skin cancer epidemiology, detection, and management. Med Clin N Am. 2015;99:1323–35.
pubmed: 26476255
doi: 10.1016/j.mcna.2015.06.002
Voelker R. Study clarifies cancer risk among people with psoriasis. JAMA. 2019;322:2273.
pubmed: 31774450
doi: 10.1001/jama.2019.18582
Xie W, Yang X, Huang H, Gao D, Ji L, Zhang Z. Risk of malignancy with non-TNFi biologic or tofacitinib therapy in rheumatoid arthritis: a meta-analysis of observational studies. Semin Arthritis Rheum. 2020;50:930–7.
pubmed: 32906027
doi: 10.1016/j.semarthrit.2020.08.007
Shelton E, Laharie D, Scott FI, Mamtani R, Lewis JD, Colombel J-F, et al. Cancer recurrence following immune-suppressive therapies in patients with immune-mediated diseases: a systematic review and meta-analysis. Gastroenterology. 2016;151:97-109.e4.
pubmed: 27039969
doi: 10.1053/j.gastro.2016.03.037
Micic D, Komaki Y, Alavanja A, Rubin DT, Sakuraba A. Risk of cancer recurrence among individuals exposed to antitumor necrosis factor therapy: a systematic review and meta-analysis of observational studies. J Clin Gastroenterol. 2019;53:e1-11.
pubmed: 28737645
pmcid: 5776073
doi: 10.1097/MCG.0000000000000865
Fiorentino D, Ho V, Lebwohl MG, Leite L, Hopkins L, Galindo C, et al. Risk of malignancy with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment Registry. J Am Acad Dermatol. 2017;77:845-854.e5.
pubmed: 28893407
doi: 10.1016/j.jaad.2017.07.013
Blauvelt A, Tsai T-F, Langley RG, Miller M, Shen Y-K, You Y, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86:827–34.
pubmed: 34798201
doi: 10.1016/j.jaad.2021.11.004
Gordon KB, Lebwohl M, Papp KA, Bachelez H, Wu JJ, Langley RG, et al. Long-term safety of risankizumab from 17 clinical trials in patients with moderate-to-severe plaque psoriasis*. Br J Dermatol. 2022;186:466–75.
pubmed: 34652810
doi: 10.1111/bjd.20818
Rahman P, Ritchlin CT, Helliwell PS, Boehncke W-H, Mease PJ, Gottlieb AB, et al. Pooled safety results through 1 year of 2 phase III trials of guselkumab in patients with psoriatic arthritis. J Rheumatol. 2021;48:1815–23.
pubmed: 33934076
doi: 10.3899/jrheum.201532
van de Kerkhof PCM, Griffiths CEM, Reich K, Leonardi CL, Blauvelt A, Tsai T-F, et al. Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:83-98.e4.
pubmed: 27180926
doi: 10.1016/j.jaad.2016.03.024
Armstrong A, Paul C, Puig L, Boehncke WH, Freeman M, Torii H, et al. Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure. Dermatol Ther (Heidelb). 2020;10:133–50.
pubmed: 31749092
doi: 10.1007/s13555-019-00340-3
Lebwohl M, Deodhar A, Griffiths CEM, Menter MA, Poddubnyy D, Bao W, et al. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis: analysis of clinical trial and postmarketing surveillance data with up to five years of follow-up. Br J Dermatol. 2021;185:935–44.
pubmed: 33829482
doi: 10.1111/bjd.20136
Mease P, Roussou E, Burmester G-R, Goupille P, Gottlieb A, Moriarty SR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arthritis Care Res. 2019;71:367–78.
doi: 10.1002/acr.23738
Gottlieb A, Lebwohl M, Liu C, Israel RJ, Jacobson A. Malignancy rates in brodalumab clinical studies for psoriasis. Am J Clin Dermatol. 2020;21:421–30.
pubmed: 32207067
pmcid: 7275023
doi: 10.1007/s40257-020-00512-4
Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2020;1–5.
Papp KA, Griffiths CEM, Gordon K, Lebwohl M, Szapary PO, Wasfi Y, et al. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up. Br J Dermatol. 2013;168:844–54.
pubmed: 23301632
doi: 10.1111/bjd.12214
Reich K, Papp KA, Griffiths CEM, Szapary PO, Yeilding N, Wasfi Y, et al. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11:300–12.
pubmed: 22395580
Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, et al. Systematic review of the real-world evidence of adalimumab safety in psoriasis registries. J Eur Acad Dermatol Venereol. 2018;32:2126–33.
pubmed: 30067882
doi: 10.1111/jdv.15203
Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda APM. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–24.
pubmed: 22562972
doi: 10.1136/annrheumdis-2011-201244
Chen Y, Friedman M, Liu G, Deodhar A, Chu C-Q. Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders? Cytokine. 2018;101:78–88.
pubmed: 27688201
doi: 10.1016/j.cyto.2016.09.013
Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, et al. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam Clin Pharmacol. 2016;30:162–71.
pubmed: 26604187
doi: 10.1111/fcp.12171
Leonardi C, Papp K, Strober B, Thaçi D, Warren RB, Tyring S, et al. Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2019;180:76–85.
pubmed: 30169904
doi: 10.1111/bjd.17084
Asgari MM, Ray GT, Geier JL, Quesenberry CP. Malignancy rates in a large cohort of patients with systemically treated psoriasis in a managed care population. J Am Acad Dermatol. 2017;76:632–8.
pubmed: 28162854
doi: 10.1016/j.jaad.2016.10.006
Trafford AM, Parisi R, Kontopantelis E, Griffiths CEM, Ashcroft DM. Association of psoriasis with the risk of developing or dying of cancer: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:1390.
pubmed: 31617868
pmcid: 6802036
doi: 10.1001/jamadermatol.2019.3056
Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, et al. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti–tumor necrosis factor agents versus classic therapies: prospective meta-analysis of Psonet registries. J Am Acad Dermatol. 2017;76:299-308.e16.
pubmed: 27693008
doi: 10.1016/j.jaad.2016.07.039
Ruderman EM. Overview of safety of non-biologic and biologic DMARDs. Rheumatology. 2012;51:vi37-43.
pubmed: 23221586
doi: 10.1093/rheumatology/kes283
Weaver JL. Establishing the carcinogenic risk of immunomodulatory drugs. Toxicol Pathol. 2012;40:267–71.
pubmed: 22105649
doi: 10.1177/0192623311427711
Solomon DH, Kremer JM, Fisher M, Curtis JR, Furer V, Harrold LR, et al. Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. 2014;43:489–97.
pubmed: 24012043
doi: 10.1016/j.semarthrit.2013.08.003
Rudzki JD. Risk of cancer after long-term therapy of autoimmune disorders with glucocorticoids or DMARDs—a controversial issue. memo. 2019;12:225–9.
doi: 10.1007/s12254-019-0506-5
Mazaud C, Fardet L. Relative risk of and determinants for adverse events of methotrexate prescribed at a low dose: a systematic review and meta-analysis of randomized placebo-controlled trials. Br J Dermatol. 2017;177:978–86.
pubmed: 28182264
doi: 10.1111/bjd.15377
Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard M-A, et al. Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies. J Eur Acad Dermatol Venereol. 2013;27:36–46.
pubmed: 23845151
doi: 10.1111/jdv.12165
Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172:369–80.
pubmed: 32066146
pmcid: 7229518
doi: 10.7326/M19-3369
Han W, Ming M, He T-C, He Y-Y. Immunosuppressive cyclosporin A activates AKT in keratinocytes through PTEN suppression: implications in skin carcinogenesis. J Biol Chem. 2010;285:11369–77.
pubmed: 20154081
pmcid: 2857015
doi: 10.1074/jbc.M109.028142
Balak DMW, Gerdes S, Parodi A, Salgado-Boquete L. Long-term safety of oral systemic therapies for psoriasis: a comprehensive review of the literature. Dermatol Ther (Heidelb). 2020;10:589–613.
pubmed: 32529393
doi: 10.1007/s13555-020-00409-4
Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol. 2005;152:597–615.
pubmed: 15840088
doi: 10.1111/j.1365-2133.2005.06563.x
Kaushik SB, Lebwohl MG. Review of safety and efficacy of approved systemic psoriasis therapies. Int J Dermatol. 2019;58:649–58.
pubmed: 30246393
doi: 10.1111/ijd.14246
Dávila-Seijo P, Dauden E, Descalzo MA, Carretero G, Carrascosa J-M, Vanaclocha F, et al. Infections in moderate to severe psoriasis patients treated with biological drugs compared to classic systemic drugs: findings from the BIOBADADERM registry. J Invest Dermatol. 2017;137:313–21.
pubmed: 27677836
doi: 10.1016/j.jid.2016.08.034
Aydin F, Yuksel EP, Senturk N, Canturk T, Turanli AY. Cancer-free survival of psoriasis patients treated with methotrexate and cyclosporine combination. Cutan Ocul Toxicol. 2014;33:181–3.
pubmed: 23944659
doi: 10.3109/15569527.2013.825805
Solomon-Cohen E, Reiss-Huss S, Hodak E, Davidovici B. Low-dose acitretin for secondary prevention of keratinocyte carcinomas in solid-organ transplant recipients. Dermatology. 2022;238:161–6.
pubmed: 33902035
doi: 10.1159/000515496
Balato A, Campione E, Cirillo T, Malara G, Trifirò C, Bianchi L, et al. Long-term efficacy and safety of apremilast in psoriatic arthritis: focus on skin manifestations and special populations. Dermatol Ther. 2020;33: e13440.
pubmed: 32306448
doi: 10.1111/dth.13440
Lambert JLW, Segaert S, Ghislain PD, Hillary T, Nikkels A, Willaert F, et al. Practical recommendations for systemic treatment in psoriasis in case of coexisting inflammatory, neurologic, infectious or malignant disorders (BETA-PSO: Belgian Evidence-based Treatment Advice in Psoriasis; part 2). J Eur Acad Dermatol Venereol. 2020;34:1914–23.
pubmed: 32791572
pmcid: 7496856
doi: 10.1111/jdv.16683
Smith CH, Jabbar-Lopez ZK, Yiu ZZ, Bale T, Burden AD, Coates LC, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. Br J Dermatol. 2017;177:628–36.
pubmed: 28513835
doi: 10.1111/bjd.15665
Capocaccia R, Gatta G, Dal Maso L. Life expectancy of colon, breast, and testicular cancer patients: an analysis of US-SEER population-based data. Ann Oncol. 2015;26:1263–8.
pubmed: 25735314
doi: 10.1093/annonc/mdv131
Papp KA, Beecker J, Cooper C, Kirchhof MG, Pozniak AL, Rockstroh JK, et al. Use of systemic therapies for treatment of psoriasis in people living with controlled HIV: inference-based guidance from a multidisciplinary expert panel. Dermatol Ther (Heidelb). 2022;12:1073–89.
pubmed: 35445963
doi: 10.1007/s13555-022-00722-0
Dickey JM. Uncertain judgements: eliciting experts’ probabilities by O’Hagan, A, Buck, C. E., Daneshkhah, A., Eiser, J. R., Garthwaite, P. H., Jenkinson, D. J., Oakley, J. E., and Rakow, T. Biometrics. 2008;64:989–90.
doi: 10.1111/j.1541-0420.2008.01082_3.x
O’Hagan A. Expert knowledge elicitation: subjective but scientific. Am Stat. 2019;73:69–81.
doi: 10.1080/00031305.2018.1518265
Lyman GH, Kuderer NM, Aapro M. Improving outcomes of chemotherapy: established and novel options for myeloprotection in the COVID-19 era. Front Oncol. 2021;11: 697908.
pubmed: 34307165
pmcid: 8299941
doi: 10.3389/fonc.2021.697908
Barreto JN, McCullough KB, Ice LL, Smith JA. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract. 2014;27:440–6.
pubmed: 25147158
doi: 10.1177/0897190014546108
Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9: e002435.
pubmed: 34172516
pmcid: 8237720
doi: 10.1136/jitc-2021-002435
Maritaz C, Broutin S, Chaput N, Marabelle A, Paci A. Immune checkpoint-targeted antibodies: a room for dose and schedule optimization? J Hematol Oncol. 2022;15:6.
pubmed: 35033167
pmcid: 8760805
doi: 10.1186/s13045-021-01182-3
Kumari S, Mukherjee S, Sinha D, Abdisalaam S, Krishnan S, Asaithamby A. Immunomodulatory effects of radiotherapy. Int J Mol Sci. 2020;21:8151.
pubmed: 33142765
pmcid: 7663574
doi: 10.3390/ijms21218151
Jiang L, Liu J. Immunological effect of tyrosine kinase inhibitors on the tumor immune environment in non-small cell lung cancer (review). Oncol Lett. 2022;23:165.
pubmed: 35414830
pmcid: 8988264
doi: 10.3892/ol.2022.13285
Ren Z, Sun J, Sun X, Hou H, Li K, Ge Q. Efficacy and safety of different molecular targeted agents based on chemotherapy for gastric cancer patients treatment: a network meta-analysis. Oncotarget. 2017;8:48253–62.
pubmed: 28477027
pmcid: 5564643
doi: 10.18632/oncotarget.17192
Wang Y, Probin V, Zhou D. Cancer therapy-induced residual bone marrow injury: mechanisms of induction and implication for therapy. Curr Cancer Ther Rev. 2006;2:271–9.
pubmed: 19936034
pmcid: 2779029
doi: 10.2174/157339406777934717
Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, et al. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18:10.
pubmed: 26810608
pmcid: 4727393
doi: 10.1186/s13058-015-0669-x
Lumniczky K, Candéias SM, Gaipl US, Frey B. Editorial: radiation and the immune system: current knowledge and future perspectives. Front Immunol. 2018;8:1933.
pubmed: 29410662
pmcid: 5787080
doi: 10.3389/fimmu.2017.01933
Lumniczky K, Impens N, Armengol G, Candéias S, Georgakilas AG, Hornhardt S, et al. Low dose ionizing radiation effects on the immune system. Environ Int. 2021;149: 106212.
pubmed: 33293042
doi: 10.1016/j.envint.2020.106212
de Carvalho HA, Villar RC. Radiotherapy and immune response: the systemic effects of a local treatment. Clinics (São Paulo). 2018;73: e557s.
pubmed: 30540123
doi: 10.6061/clinics/2018/e557s
Standish LJ, Torkelson C, Hamill FA, Yim D, Hill-Force A, Fitzpatrick A, et al. Immune defects in breast cancer patients after radiotherapy. J Soc Integr Oncol. 2008;6:110–21.
pubmed: 19087768
pmcid: 2845471